Subscribe To

Price Alert Latest News Economic Calendar News

MTP / Midatech Pharma boosted by European news on key product

Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal product designation for its development programme of MTX110 for the treatment of glioma Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients. Read More

Demo Live Account See Partner Details

Content Topics

Midatech

Pharma

Boosted

European

News

Product

Stock

MTP

Posted: Jun 21 2022, 04:01

Author Name: Proactive Investors

MTP News

By InvestorPlace
March 28, 2023

Why Is Midatech Pharma (BDRX) Stock Up 64% Today?

Midatech Pharma (NASDAQ: BDRX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a

By Proactive Investors
December 14, 2022

Midatech Pharma plc continues to plummet on news of London delisting

Midatech Pharma PLC (AIM:MTPH) fell another 13% to 3p on Wednesday, having now slashed its market valuation by half in the past five days. A day earli

By Proactive Investors
June 21, 2022

Midatech Pharma boosted by European news on key product

Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Me

By Benzinga
June 1, 2022

Midatech Pharma's Shares Shoot Higher On FDA Fast Track Designation For Malignant Brain Tumor Drug

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for t

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.